XYRA, Announces

XYRA Announces Successful FDA End of Phase 2 Meeting and Agreement on Endpoints for Approval of Budiodarone for the Management of Atrial Fibrillation

Published on 08/07/2025 at 18:03 | prnewswire.co.uk

XYRA United Kingdom England United States of America California

en | boerse | 67995182 |